Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Seres Therapeutics, Inc. MCRB

Set alert

Price alert · MCRB

All alert types
1.83 USD +0.06 +3.39%

At close

1.95 +0.12 +6.56%

Pre-market · Nov 3, 5:49 AM ET

Bid
1.83 × 2
Ask
1.84 × 2
1.82 Day range 2.00
1.68 52-week range 29.98
YTD
-87.70%
1 year
-88.63%
Open
1.84
Prev close
1.77
Mkt cap
18.38M
Vol
44.16K
Avg vol
69.28K
EPS
-2.42
P/E
0.00
Div yield
0.00%
More statistics
Low
1.82
High
2.00
Forward P/E
-1.75
Beta
0.00
Short ratio
5.18
Inst. own
37.15%
Dividend
0.00
Ex-div date
50-d avg
0.7989
200-d avg
0.88022
1y target
3.87

MAX chart

Chart tools
Interval
1m5m15m30m

Chart is warming up

The all-time price history for MCRB has not been loaded yet. Try again in a moment.

Analyst view

Consensus: buy

Buy
Price target (mean) 3.87 +111.7% upside
Target (low)
1.00
Target (mean)
3.87
Target (high)
10.00
Ratings (0m) 7 4 buy · 1 hold · 2 sell
  • Strong buy0
  • Buy4
  • Hold1
  • Sell0
  • Strong sell2

Recommendation trend

  • This month 7
  • 1 month ago 7
  • 2 months ago 7
  • 3 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

MCRB analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.21446-0.28 – -0.13-0.2766+22.5%0-100.0%4
Next quarter-0.19-0.26 – -0.12-0.27+29.6%12.50M0.0%2
Current year-0.52304-0.94 – -0.10607-0.8447+38.1%0-100.0%2
Next year-0.40918-0.82 – -0.02-0.52304+21.8%34.84M0.0%4

Upgrades and downgrades

The latest rating changes

MCRB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024Canaccord GenuityMaintainedBuyBuy
Nov 13, 2024Chardan CapitalMaintainedBuyBuy
Oct 24, 2024JP MorganDowngradeNeutralUnderweight
Sep 13, 2024Canaccord GenuityMaintainedBuyBuy
Aug 14, 2024Canaccord GenuityMaintainedBuyBuy
Aug 14, 2024Chardan CapitalMaintainedBuyBuy
Jun 7, 2024OppenheimerDowngradeOutperformPerform
Jun 7, 2024Canaccord GenuityMaintainedBuyBuy
May 9, 2024OppenheimerMaintainedOutperformOutperform
May 8, 2024Chardan CapitalMaintainedBuyBuy
Mar 6, 2024OppenheimerMaintainedOutperformOutperform
Mar 6, 2024Chardan CapitalMaintainedBuyBuy
Jan 16, 2024OppenheimerMaintainedOutperformOutperform
Nov 3, 2023Goldman SachsMaintainedSellSell
Apr 28, 2023Chardan CapitalMaintained—Buy
Apr 21, 2023JP MorganInitiated—Neutral
Mar 21, 2023Canaccord GenuityMaintained—Buy
Mar 8, 2023Canaccord GenuityMaintained—Buy
Mar 8, 2023Chardan CapitalReiterated—Buy
Mar 8, 2023HC Wainwright & Co.Reiterated—Buy
Feb 8, 2023HC Wainwright & Co.Reiterated—Buy
Sep 7, 2022Piper SandlerMaintained—Overweight
May 23, 2022Piper SandlerMaintained—Overweight
Jul 23, 2021Canaccord GenuityMaintained—Buy
Jul 23, 2021Chardan CapitalMaintained—Buy
Jul 23, 2021OppenheimerMaintained—Outperform
Jul 23, 2021HC Wainwright & Co.Maintained—Buy
Jul 23, 2021Goldman SachsDowngradeNeutralSell
May 5, 2021HC Wainwright & Co.Maintained—Buy
Mar 5, 2021Chardan CapitalUpgradeNeutralBuy